Smallpox vaccine(Bavarian Nordic A/S)

今日要闻(2025.11.3~11.9）四川进入流感流行期，省疾控提醒尽快接种疫苗联合国儿基会祝贺中国启动13岁女孩HPV疫苗免费接种意大利北部11月确诊370例本地传播基孔肯雅热病例高新区进社区开展狂犬病疫苗公益接种活动：四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验欧洲通过HERA框架协议订购75万剂2026年猴痘疫苗孕妇四价流感疫苗（慧尔康欣 ®）研究中期进展，填补国内空白默沙东携HPV疫苗等成果亮相进博会，未来五年将引入40余项医疗新品全球第二大流感疫苗生产商CSL押注美国流感疫苗接种反弹香港确诊第三例本地基孔肯雅热病例贵州仁怀：多举措推进流感疫苗接种 守护民众健康塞力医疗：治疗性降压疫苗HJY-ATRQβ-001注射液获伦理批件长春祈健水痘疫苗扩龄获批，助力青成人防控以“防治结合”新格局，加速突破性疫苗和药物的研发与落地流感季多地四价流感疫苗供应紧张，企业加大供应应对官方发布四川进入流感流行期，省疾控提醒尽快接种疫苗据中国疾控中心监测，我国南方省份流感活动上升。四川省疾控中心发布提醒，四川已进入流感流行期，主要流行毒株为甲型H3N2流感病毒。流感并非“小感冒”，对老人、儿童等群体危害较大。接种流感疫苗是预防流感最有效、经济的手段，6月龄以上且无接种禁忌者均可接种，尤其建议儿童、孕妇、老人及慢性病患者接种。接种后约2-4周产生保护抗体，整个流行季接种都有益。此外，接种前要如实告知健康状况等，处于急性疾病发作期应推迟接种，日常也需做好勤洗手、多通风等防护措施。来源：金台资讯联合国儿基会祝贺中国启动13岁女孩HPV疫苗免费接种11月10日，我国将HPV疫苗纳入国家免疫规划，年满13周岁女孩可免费接种双价HPV疫苗，联合国儿基会与世卫组织对此表示祝贺，称这是保护女孩免患宫颈癌、推动健康公平与性别平等的历史性举措。宫颈癌每年致全球超34万人死亡，中国病例和死亡数占比不低。世卫组织目标是 2030年90%女孩15岁前完HPV疫苗接种。儿基会驻华代表桑爱玲指出此政策是重要里程碑，该机构将凭全球经验支持中国，助力缩小接种差距，保障女孩健康与成长。来源：澎湃新闻流感季多地四价流感疫苗供应紧张，企业加大供应应对流感季已至，广州、西安、常州等多地接种点公告四价流感疫苗阶段性紧张或缺货，四价裂解疫苗因价低需求激增缺货，四价亚单位疫苗因仅江苏中慧生物生产（年产400万剂）且受宣传带动需求增长而供应紧。此次缺苗与流感季提前、疫苗配送时间差有关。华兰生物等企业正加大供应，广州市荔湾区等地预计11月中下旬供应趋足。目前南北方流感样病例比例上升，中国流感疫苗接种率低（2022-2023季仅3.8%），但批签发量和接种率预计将逐步提升。来源：网络低代次Vero细胞：驱动狂犬病疫苗技术革新的核心力量狂犬病疫苗研发中，细胞基质是关键。早期疫苗用神经组织等原始基质，产量低、副作用大且不稳定；如今低代次Vero细胞成技术 “新星”，推动疫苗进入精密制造阶段。其创新点显著：卓谊生物将细胞代次控制在140代内（严于WHO150代标准），保障安全；搭配与国内流行毒株亲缘近的CTN-1毒株，提升防护效率；还通过全链条质控确保品质。该细胞可大规模培养以应对全球需求，生产的疫苗质量稳定，为行业树标杆，其技术经验还将助力其他疫苗研发，开启疫苗新时代。来源：网络默沙东携HPV疫苗等成果亮相进博会，未来五年将引入40余项医疗新品第八届进博会开幕，默沙东连续七年参展，以“创新科学，健康未来”为主题展示医疗创新成果及本土合作布局。其展陈约30种已获批药物和疫苗，覆盖多领域，含多款“进博首秀”产品。借助进博会溢出效应，去年在研药物已陆续获批，惠及患者。默沙东还展示在研管线，未来五年拟向中国引入40多项新产品和新适应证。其HPV疫苗已保护超5000万中国女性，今年获批男性适用，肿瘤领域也有32个适应证获批。此外，默沙东将举办主题活动及患者援助项目纪念仪式。来源：上观新闻香港确诊第三例本地基孔肯雅热病例近日，香港特区政府卫生署卫生防护中心宣布，葵青区一名中年男子确诊为第三例本地感染基孔肯雅热病例，该男子在上环工作。截至11月4日，防护中心正开展基因组分析，以确认其与此前香港输入病例是否存在流行病学关联，相关调查仍在进行中。香港首宗基孔肯雅热病例于10月28日报告，此次新病例出现后，防护中心已与多部门及相关机构召开跨部门会议。此外，美国疾控中心曾于8月底发布二级旅行健康提示，提醒国际旅行者防范该地区基孔肯雅热风险，并建议通过防蚊、接种疫苗（孕妇需延后接种）等方式防护，美国旅行诊所及药房已提供获批疫苗。来源：vax-before-travel贵州仁怀：多举措推进流感疫苗接种 守护民众健康秋冬流感高发期，贵州仁怀市疾控部门多措并举推进流感疫苗接种。盐津街道卫生服务中心接种门诊，市民接短信提醒后有序接种，市民蔡小燕称带娃接种护己护人。针对H3N2流感病毒活动增强，仁怀首次短信提醒居民，还多渠道宣传防控知识。疾控中心建议易感人群优先接种，目前各乡镇均有接种点且疫苗充足，全力筑牢全民健康防护网。来源：网络塞力医疗：治疗性降压疫苗HJY-ATRQβ-001注射液获伦理批件近日，由塞力医疗战略控股子公司华纪元生物发起，斯丹姆（北京）医药作为CRO的I期临床试验项目，正式获得华中科技大学同济医学院附属协和医院医学伦理委员会的审查批件。这标志着由塞力医疗战略投资的这款名为“HJY-ATRQβ-001注射液（血管紧张素Π受体I型治疗性降压疫苗）”的创新药物，在正式进入人体临床试验阶段的道路上迈出了坚实而关键的第一步。来源：第一财经世卫组织将为4.4万名加沙儿童接种疫苗近日，世卫组织计划9日起在加沙地带启动大规模疫苗接种，10 天内为4.4万名儿童完成麻疹、腮腺炎等疫苗首轮接种，明年1月进行后续接种，以填补两年冲突造成的免疫空白。此前，世卫曾在2024年夏季和2025年2月开展过脊髓灰质炎疫苗接种，但部分儿童未覆盖。本轮巴以冲突致加沙5岁以下儿童约20%未接种或接种不足，总体接种率从98%降至不足70%。接种期间，联合国儿童基金会还将评估儿童营养不良情况以提供针对性援助。来源：新华社全球第二大流感疫苗生产商CSL押注美国流感疫苗接种反弹近期，全球第二大流感疫苗生产商澳大利亚CSL Ltd.预测，受全球卫生团体反击疫苗错误信息、新一轮流感关联疾病发病率上升推动，美国流感疫苗接种规模将大幅反弹。其疫苗部门Seqirus总经理Dave Ross称美市场中期将显著复苏，但未给时间表。新冠疫情后，疫苗错误信息致美国年接种人数减约6000万，引发严重流感季，目前医疗团体正推广科学建议。此前因美接种率下滑，CSL推迟Seqirus分拆上市，股价承压。Seqirus聚焦欧洲增长，助CSL流感疫苗全球市占率升至42%，与赛诺菲、GSK共占主要市场。来源：智通财经湖北省流感上升，当前接种疫苗仍可行湖北省流感活动呈上升趋势，流行毒株以甲型 H3N2 为主，该毒株并非新毒株，症状有高热、咽喉痛等。每年接种流感疫苗是预防关键，因病毒易变异且抗体水平会衰减。虽最佳接种时间为 9-10 月，但整个流行季接种仍可，接种后 2-4 周产生保护抗体。我国三价、四价流感疫苗均覆盖 H3N2，四价还含另一种乙型毒株，可自愿选择，可通过 “洪山疾控” 公众号预约。建议≥6 月龄无禁忌者接种，医务人员、老人、慢性病患者等为优先人群。来源：网络高新区进社区开展狂犬病疫苗公益接种活动11月1日，高新区街道办与区动物疫控中心在益民园社区办狂犬病疫苗公益接种活动，居民有序排队，专家答疑，宠物登记免疫高效推进。狂犬病病死率近100%但可预防，此次政企协作服务意义重大。活动获多单位响应，怡安生物提供无痛预充装疫苗，获市民认可。主办单位称将持续防控，助力2030年实现狂犬病全面净化，护航健康平安唐山。来源：新浪财经企业动态康泰生物：四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验11月3日电，康泰生物(300601)11月3日公告，公司研发的四价流感病毒裂解疫苗（6-35月龄人群）已完成Ⅰ期临床试验准备工作，开启Ⅰ期临床试验，并于近日成功完成首例受试者入组。来源：人民财讯孕妇四价流感疫苗（慧尔康欣 ®）研究中期进展，填补国内空白近日，孕妇接种四价流感病毒亚单位疫苗（慧尔康欣 ®）安全性和免疫效果研究中期总结会在渝召开。该研究由中慧生物等联合启动，为 “孕期接种流感疫苗安全” 的国际共识填补中国人群佐证空白，还能支撑提升孕妇疫苗接种率、降低母婴健康风险。此疫苗纯度高、安全性好，已获批扩龄至 6 月龄及以上，是我国首款全人群全剂量四价流感亚单位疫苗，为流感防控提供更广人群保护。来源：中慧生物长春祈健水痘疫苗扩龄获批，助力青成人防控近日，长春祈健生产的水痘减毒活疫苗获国家药监局批准，接种对象新增13岁及以上人群，现覆盖12月龄以上所有年龄，可助力青成人水痘防控。水痘易在人群聚集处暴发，近年发病率上升且发病年龄后移，校园水痘疫情防控成本高、影响教学。该疫苗相关 Ⅲ 期临床试验、上市后评价均证明其安全性与有效性，生产工艺领先，还出口多地区，累计接种近亿剂次。来源：网络以“防治结合”新格局，加速突破性疫苗和药物的研发与落地葛兰素史克连续八年参展进博会，以 “防治结合、全生命周期健康管理” 为布局理念，展示对中国健康生态的深度参与。此次带来多款创新管线产品，如全球首款获批上市、在中国开展三期临床的RSV疫苗，有望实现慢性乙肝 “功能性治愈” 的ASO类药物，六个月一次长效给药的德莫奇单抗，针对多发性骨髓瘤的抗 BCMA 抗体偶联药物等。曾的 “进博宝宝” 欣安立适和新可来也携新适应症回归。GSK积极响应 “医防协同”，加速疫苗和药物研发落地，让中国患者同步共享成果。来源：网络国际新闻意大利北部11月确诊370例本地传播基孔肯雅热病例2025年11月意大利流行病学数据显示，基孔肯雅热是经受感染蚊子传播的病毒性疾病，首起已知疫情于1952年发生，过去一年全球100国向欧洲疾控中心报告疫情。意大利2025年已报告419例基孔肯雅热病例，约370例为本地传播，主要集中在北部。欧洲疾控中心10月29日报告显示，意大利病例主要聚集在卡尔皮等多地。美国自2019年无本地感染病例，但 2025 年 11 月底确诊 19 例旅行相关病例，部分与古巴访客有关，美疾控中心建议赴疫情地区旅行者咨询疫苗接种，2025年11月诊所和药店将提供获批疫苗。来源：vax-before-travel730万美元资助ChAdOx1 NipahB候选疫苗研发美国疾控中心消息，尼帕病毒致死率达40%-75%，2025年孟加拉国和印度出现相关死亡病例，目前尚无预防疫苗。近期，流行病防范创新联盟（CEPI）、牛津大学与全球最大疫苗制造商印度血清研究所合作，研发尼帕病毒新防御方案，目标建立最大候选疫苗试验储备。CEPI 提供的730万美元将支持印度血清研究所研发、生产牛津大学的ChAdOx1 NipahB候选疫苗。该研究所将生产用于尼帕病毒疫区 II 期临床试验的疫苗，还将建立10万剂试验储备，以备疫情应急使用，此次II期试验也将是全球首个尼帕病毒候选疫苗II期试验。此前2025年，CEPI与美国国防部已联合开展尼帕病毒防治工作。来源：vax-before-travel特定男性群体仍面临中度猴痘健康风险2025 年11月，世界卫生组织发布猴痘多国疫情第59期情况报告。截至11月2日，猴痘病毒所有分支仍在全球传播，2025年9月42国报告3135例确诊病例、12例死亡，超80%病例来自非洲区域。世卫组织评估，在非历史流行区，男男性行为者面临中度猴痘健康风险，普通人群风险较低。刚果（金）已接种超 68.4 万剂 MVA-BN 疫苗和1.18万剂LC16疫苗，占非洲国家接种人数超61%。其他报告猴痘疫情国家正制定疫苗接种计划，美国部分机构为高风险人群提供 JYNNEOS 疫苗，各方也在推进疫苗供应与资金保障。来源：vax-before-travel口服候选疫苗CVD1902对甲型副伤寒具有显著保护作用牛津大学主导研究显示，口服减毒候选疫苗CVD1902能有效保护成人免受甲型副伤寒沙门氏菌感染，且无安全隐患。肠热症（由伤寒、甲型副伤寒沙门氏菌引发）每年致超10万人死亡，损失超800万年健康寿命，其中30%（年超200万例）由甲型副伤寒导致，目前尚无对应疫苗。美疾控中心称，美国多数肠热症患者因国际旅行感染。该研究获英医学研究理事会等资助，成果发表于《新英格兰医学杂志》。来源：vax-before-travel欧洲通过HERA框架协议订购75万剂2026年猴痘疫苗世界卫生组织指出，猴痘疫情仍是全球健康风险，而猴痘可通过疫苗预防，获取获批疫苗至关重要。近日，全球疫苗企业巴伐利亚北欧公司就卫生应急准备与响应局（HERA）框架协议澄清：欧盟委员会通过 HERA 新联合采购合同，于 2025年 10月31日宣布订购 75 万剂 MVA-BN（JYNNEOS）天花 / 猴痘疫苗，将于 2026 年交付。这是该公司2025年收到的第二笔订单，此前5月曾获美国卫生与公众服务部下属机构的合同期权。该公司预计未来一年还会收到更多 MVA-BN 疫苗订单，且截至 2025年11月3日，JYNNEOS 疫苗已在美国多家医疗诊所和药店商业化供应。来源：vax-before-travel武田第二代登革热疫苗QDENGA获七年保护期数据日本武田公司的第二代登革热疫苗QDENGA，自 2022 年在印尼首获批准后，已在41国获批、11个登革热流行国供应。2025年11月3日，该公司宣布七年关键III期TIDES试验完成，数据证实其两剂方案具持续保护力， booster剂量探索性分析也验证了获益 - 风险特征，与多国获批适应症一致。武田全球疫苗业务总裁称，该疫苗临床项目覆盖超6万全球受试者，长期数据彰显其在不同人群中的安全性与有效性持久性。目前武田仍推进上市后研究，而美国佛罗里达2025年报告53例本地感染登革热病例，但 QDENGA 暂未在美国上市。来源：vax-before-travel阿根廷登革热病例数显著下降2025年11月，泛美卫生组织（PAHO）报告，阿根廷今年登革热病例数呈下降趋势。此前2024年美洲登革热病例意外激增，PAHO聚焦南美南锥体次区域（含阿根廷等国），并公开数据以提示国际旅行者。截至2025年11月4日，阿根廷累计报告登革热病例17689例、死亡17例，病例数较 2024年的超58万例大幅减少，且于2025年5月达峰后回落。过去一年，阿根廷中部和西北部地区检测出 DENV-1、DENV-2、DENV-3三种登革热血清型。美国疾控中心称2025年疫区居民及旅行者有感染风险，但阿根廷暂未被列入其全球健康公告。来源：vax-before-travelZika候选疫苗VLA1601二期临床试验显示免疫应答增强效果1952年Zika病毒（ZIKV）首现人类病例，31个国家和地区报告其引发的先天性小头症等病症。法国疫苗公司 Valneva 针对该需求开展二期临床试验，研究第二代佐剂灭活候选疫苗 VLA1601 的安全性与免疫原性。截至 2025 年11月4日，结果显示两剂VLA1601在所有试验组均具免疫原性，双佐剂组免疫应答最强，中和抗体滴度显著高于单佐剂组，且较一代疫苗，血清转化率（>93% vs 86%）和滴度增幅（>56 倍 vs >7 倍）更高。若获FDA批准，国际旅行者尤其是孕妇或将受益。今年美洲地区已报告超2.4万例 Zika 病例及4例死亡。来源：vax-before-travel2025年末美国佛罗里达州仍有基孔肯雅热、登革热及疟疾病例11月1日，美国佛罗里达州卫生部发布2025年第44期疫苗可预防疾病监测报告，显示该州仍有本地感染及旅行相关的蚊媒传染病病例，病例主要集中在东南部沿海地区。报告显示，今年该州已确认42例旅行相关基孔肯雅热病例，涉及多个县，感染源来自玻利维亚等国；321例旅行相关登革热病例，超180例与古巴旅行者相关，另有53例本地登革热病例；41例旅行相关疟疾病例，15例与尼日利亚旅行相关。目前多县发布蚊媒疾病预警或警报，但美国疾控中心暂未针对佛罗里达发布旅行健康通知。来源：vax-before-travel《循环》：科学家发现，新冠mRNA疫苗编码的S蛋白具有心脏蛋白同源表位，诱发急性心肌心包炎近期，《循环》杂志发表伦敦玛丽女王大学研究，揭示新冠 mRNA疫苗致急性心肌心包炎（AMP）的机制。mRNA疫苗编码的S蛋白含与心脏蛋白同源的表位（如PS5、P87），可被具心脏归巢能力的cMet阳性T细胞识别。这些T细胞会攻击心脏蛋白，在易感个体中诱发AMP。研究还发现，疫苗相关AMP与新冠感染诱发机制不同，且未来疫苗设计应避免使用与关键器官蛋白同源的抗原片段，以降低风险。AMP病程轻，发生率约106例/10万，部分无症状患者或未被诊断。来源：网络德克萨斯州百日咳病例同比激增超80%2025年11月3日更新的德州卫生服务部（DSHS）临时数据显示，该州今年截至10月已报告超3500例百日咳病例，较去年同期的1907例约增4倍，较2023年全年 340 例大幅上升，且这是该州连续两年病例同比高增、DSHS连续两年发健康警报。DSHS指出，未完全接种疫苗的婴幼儿易出现严重甚至致命并发症，接种疫苗是最佳预防方式，但接种者仍可能患病，症状或较轻且无典型 “百日咳” 声。此外，美国疾控中心2024年初步数据显示全美病例数为2023年的6倍多，目前德州卫生诊所和药店可提供百日咳疫苗。来源：vax-before-travel多国就赴哥斯达黎加旅行发布提示（聚焦安全与健康风险）加拿大政府重新发布赴哥斯达黎加旅行指南，自10月28日起，因该国城市中心及沿海地区犯罪频发，建议游客保持高度警惕，虽未禁止旅行，但强调需提高防范意识，加拿大驻圣何塞使馆可为当地加公民提供支持。哥斯达黎加每年吸引数千加公民前往，2025年初已有超14.3万人次到访。此外，美国疾控中心也将哥斯达黎加纳入多项健康提示，该国不仅出现曾被消除的新大陆螺旋蝇向北扩散情况，今年还报告了基孔肯雅热、登革热、疟疾、麻疹及寨卡病毒感染病例，且不同地区感染率存在差异。来源：vax-before-travel研究证实：新冠疫苗可降低青少年感染后长新冠风险2025年11月6日，哥伦比亚大学欧文医学中心参与的新研究显示，接种新冠疫苗的青少年，首次感染新冠病毒后患长新冠的概率低于未接种同龄人。该研究由美国国立卫生研究院资助的RECOVER项目主导，是首个探究新冠疫苗除减轻初始症状外，对青少年额外益处的研究。研究纳入美国1200余名青少年，其中724人在首次感染前半年接种疫苗，507人未接种。结果显示，未接种者长新冠风险超20%，接种者约13%，风险降低 36%。此前成人相关研究已证实疫苗的该作用，但青少年群体证据有限。研究作者指出，此发现或助力青少年感染后恢复正常生活。来源：medical高剂量流感疫苗在预防住院与感染方面优于标准剂量近日，两项新分析表明，高剂量流感疫苗（HD-IIV）在预防住院和感染上比标准剂量疫苗（SD-IIV）更有效。首项发表于《柳叶刀》的研究，分析丹麦、西班牙两项试验的46.6 万余名平均73.3岁老年人数据，发现 HD-IIV 组流感或肺炎住院率0.56%（SD-IIV 组 0.62%），流感住院风险降31.9%，全因住院风险降2.2%，预防 1 例全因住院需为515名老人接种HD-IIV。第二项发表于《国际传染病杂志》的研究，分析意大利81.1岁左右老年人数据，HD-IIV组实验室确诊流感率6.6%（SD-IIV 组10.3%），感染防护率高29%，80岁及以上人群中该优势更显著。来源：umn* 此文仅用于向医学人士提供科学信息，不代表本平台观点本文仅作为科普传播素材，文中涉及药物、技术、产品等只做表达所需，不具任何治疗建议，具体治疗方式请前往正规医院接受专业检查及治疗。部分图片素材来自网络，非商业用途，若有侵权，请联系我们删除，谢谢！

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 6 November, 2025 – With reference to company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary board-recommended public takeover offer to acquire all of the issued and outstanding shares (except treasury shares) in Bavarian Nordic A/S ("Bavarian Nordic") by Innosera ApS (the "Offeror"), a company controlled by Nordic Capital Fund XI1 and funds managed and advised by Permira Beteiligungsberatung GmbH (the "Offer"), the Offeror has today announced the preliminary result of the Offer pursuant to section 21(3) of the Danish Executive Order no. 614 of 2 June 2025 on Takeover Offers (the "Danish Takeover Order"). According to the terms and conditions of the Offer, the offer period expired yesterday, 5 November 2025 at 11:59 p.m. (CET). The Offeror has informed Bavarian Nordic that, based on the Offeror's preliminary and non-binding calculation of acceptances, the rate of acceptances under the minimum acceptance condition corresponds to 60% compared to the threshold of 66 2/3%. As the minimum acceptance condition has therefore not been satisfied, the Offeror has informed Bavarian Nordic that it has resolved to withdraw the Offer in accordance with section 5.11 of the offer document. As a result, the Offer has irrevocably lapsed and will not be completed. All acceptances of the Offer are without legal effect. No shares will be acquired under the Offer, and no consideration will be paid to shareholders who have tendered their shares. Luc Debruyne, Chair of the Board of Directors of Bavarian Nordic, said:"60% have accepted the takeover offer from Nordic Capital and Permira. However, this does not meet the acceptance rate threshold of 66.7% and thus the bid will not go through. We acknowledge and respect the decision made by shareholders, which means that Bavarian Nordic will continue as an independent listed company with its current growth strategy. Bavarian Nordic is a profitable and strong company well positioned to continue to grow, and the Board of Directors has the full confidence in the management's continued execution of the strategy, including considerations for ways to accelerate value creation. The Board and management now see an opportunity to re-build a value creating dialog with shareholders and stakeholders of Bavarian Nordic as an independent public company. This includes an invitation to a shareholders’ information meeting to be held early December. Further details will be published soon, but the agenda will include 1) the state of business, 2) recap of the company strategy and financial ambitions and 3) the need to ensure continuity of leadership, while at the same time ensuring a team of board members adapted to set the strategic direction for the company." Contact investors:Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 40 / 2025 Attachments: Innosera ApS announces results of the takeover offer to the shareholders of Bavarian Nordic A/S – minimum acceptance condition not satisfied – the offer is withdrawn and will not be completed About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. DISCLAIMERSThis announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell any securities and is neither a tender offer document nor a prospectus for the purposes of EU regulation 2017/1129, and as such does not constitute or form part of an offer or invitation to make a sales offer in any jurisdiction. This announcement is not directed at shareholders of Bavarian Nordic resident in any jurisdiction in which the submission of the Offer, or acceptance thereof, or this announcement would contravene the law of such jurisdiction. Accordingly, neither this announcement nor any other material regarding the Offer may be distributed in any jurisdiction outside of Denmark or United States, if such distribution would require any registration, qualification, or other requirement in respect of any offer to purchase or sell securities or distribute documents or advertisements in respect thereof. Any person acquiring possession of this announcement or any other document referring to the Offer is expected and assumed to obtain on his or her own accord any necessary information on any applicable restrictions and to comply with such restrictions. This announcement does not constitute an offer or invitation to purchase any securities in Bavarian Nordic or a solicitation of an offer to buy any securities, pursuant to the Offer or otherwise. The Offer is made solely by means of the offer document (as amended by the supplements) approved by the Danish Financial Supervisory Authority, which contains the full terms and conditions of the Offer, including details of how the Offer may be accepted. Shareholders in Bavarian Nordic are advised to read the offer document (as amended by the supplements) and the related documents as they contain important information. The Offer is subject to the laws of Denmark. The offer document (as amended by the supplements), the board statements and this announcement have been drawn up in the Danish and English languages. In the event of any discrepancy between the two language versions of the offer document, the supplements, and the board statements, the Danish language version will prevail. The Offer relates to the securities of a Danish company and is subject to the disclosure requirements applicable under Danish law, which may be different in material aspects from those applicable in the United States. For shareholders residing or precedent in the United States, please see notice below. Forward looking statementsThis announcement may contain, in addition to historical information, forward-looking statements related to the proposed tender offer. When used in this announcement, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Offeror and Bavarian Nordic or the Offer identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. Such statements are based on the Offeror’s and management’s current expectations and are subject to a number of uncertainties and risks, which could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements included in this announcement are based on information available to Bavarian Nordic as of the date of this announcement, and except to the extent Bavarian Nordic may be required to update such information under any applicable securities laws, Bavarian Nordic assumes no obligation to update such forward-looking statements. Restricted jurisdictionsThe Offer is not made, and the Bavarian Nordic shares will not be accepted by the Offeror for purchase from or on behalf of persons, in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws or regulations of such jurisdiction. Persons obtaining this announcement and/or into whose possession this announcement comes are required to take due note and observe all such restrictions and obtain any necessary authorizations, approvals or consents. Neither Bavarian Nordic nor any of its advisors accepts any liability for any violation by any person of any such restriction. Any person (including, without limitation, custodians, nominees and trustees) who intends to forward this announcement to any jurisdiction outside Denmark should inform themselves of the laws of the relevant jurisdiction, before taking any action. The distribution of this announcement in jurisdictions other than Denmark may be restricted by law, and, therefore, persons who come into possession of this announcement should inform themselves about and observe such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws and regulations of any such jurisdiction. Notice to shareholders in the United StatesThe Offer is subject to the laws of Denmark. The Offer relates to the securities of a Danish company and is subject to the disclosure requirements applicable under Danish law, which may be different in material respects from those applicable in the United States. The Offer is being made in the United States in compliance with Section 14(e) of, and applicable provisions of Regulation 14E promulgated under, the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), and otherwise in accordance with the requirements of Danish law. The Offer is not subject to Section 14(d)(1) of, or Regulation 14D promulgated under, the Exchange Act. The Offer is subject to disclosure and procedural requirements that may be different from those applicable to U.S. domestic tender offers, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered), and waivers of conditions. In addition, any financial information included in the offer documents may not have been prepared in accordance with generally accepted accounting principles in the United States and thus may not be comparable to financial information relating to U.S. companies. Shareholders whose place of residence, seat, or habitual residence is in the United States (“U.S. Shareholders”) are encouraged to consult with their own advisors regarding the Offer. The Offer is being made to U.S. Shareholders on the same terms and conditions as those made to all other shareholders to whom the Offer is made. Any information documents, including the offer to purchase, are disseminated to U.S. Shareholders on a basis reasonably comparable to the method that such documents are provided to other shareholders. It may be difficult for U.S. Shareholders to enforce certain rights and claims they may have arising in connection with the Offer under U.S. securities laws, since the Offeror and Bavarian Nordic are located in non-U.S. jurisdictions, and some or all of their respective officers and directors are residents of non-U.S. jurisdictions. U.S. Shareholders may not be able to sue the Offeror or Bavarian Nordic and/or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may not be possible to compel the Offeror or their respective affiliates, as applicable, to subject themselves to the judgment of a U.S. court. The receipt of cash pursuant to the Offer by a U.S. Shareholder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each U.S. Shareholder is urged to consult its independent professional advisor immediately regarding the tax consequences to such U.S. Shareholder of accepting the Offer. In accordance with customary Danish practice and to the extent permitted by applicable law, including Rule 14e-5(b) of the Exchange Act, the Offeror or any affiliates or nominees or brokers of the foregoing (acting as agents or in a similar capacity), may from time to time make certain purchases of, or arrangements to purchase, shares (or any securities that are convertible into, exchangeable for or exercisable for such shares) outside of the U.S., other than pursuant to the Offer, before or during the period in which the Offer remains open for acceptance. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. If, prior to completion of the Offer, the Offeror or any affiliates or any nominee or broker of the foregoing acquires Shares at a higher price than the offer price, the Offeror will increase the offer price correspondingly as required by applicable law. In addition, affiliates of the financial advisors to the Offeror may also engage in ordinary course trading activities in securities of Bavarian Nordic, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with applicable law and regulation. Any information about such purchases will be announced through Nasdaq Copenhagen and relevant electronic media if, and to the extent, such announcement is required under applicable law or regulation. Neither the U.S. Securities and Exchange Commission nor any securities commission or other regulatory authority in any state of the United States has approved or declined to approve the Offer or any offer documents, passed upon the fairness or merits of the Offer, or provided an opinion as to the accuracy or completeness of this announcement or any other documents regarding the Offer. Any declaration to the contrary constitutes a criminal offense in the United States. This announcement is not intended for distribution in any jurisdiction where such distribution would violate applicable law or regulation. The Offer is being made only through the official offer documents and only to such persons and in such jurisdictions as permitted under applicable law. No recommendation is made as to whether holders of securities should tender their securities in connection with the Offer. Holders of securities should consult their own financial, legal, and tax advisors before making any decision regarding the Offer. 1 “Nordic Capital Fund XI” refers to Nordic Capital Epsilon SCA, SICAV-RAIF (acting through its general partner Nordic Capital Epsilon GP SARL) for and on behalf of its compartment Nordic Capital Epsilon SCA, SICAV-RAIF - Compartment 2. “Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”. Attachments Company Announcement no. 40 / 2025 Innosera ApS announces results of the takeover offer to the shareholders of Bavarian Nordic A/S – minimum acceptance condition not satisfied – the offer is withdrawn and will not be completed